Research
Hormonal
GLP-1-based medications can achieve up to 24% weight loss, aiding in the effective management of obesity and its complications.
Practitioners can consider GLP-1 medications as a viable option for weight management in obese patients.
StrongSupportsmedium confidence
These new antiobesity medications can reach up to 24% weight loss, which makes possible an effective management of obesity and its complications.
Why this rating
The claim is based on the development and efficacy of new medications as stated in the abstract.
Source
GLP-1-based medications: Mechanisms involved in obesity treatment
Javier Salvador · Medicina Clínica (English Edition) · 2025
DOI 10.1016/j.medcle.2025.107035
reviewCited 2×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →